Total Payments
$29,735
2022 Payments
$47.60
Companies
11
Transactions
52
Medicare Patients
1,382
Medicare Billing
$341,825
Payment Breakdown by Category
Consulting$22,638 (76.1%)
Travel$3,724 (12.5%)
Research$1,941 (6.5%)
Food & Beverage$1,319 (4.4%)
Education$113.94 (0.4%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $22,638 | 6 | 76.1% |
| Travel and Lodging | $3,724 | 14 | 12.5% |
| Unspecified | $1,941 | 2 | 6.5% |
| Food and Beverage | $1,319 | 21 | 4.4% |
| Education | $113.94 | 9 | 0.4% |
Payments by Type
General
$27,794
50 transactions
Research
$1,941
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $18,006 | 24 | $0 (2019) |
| Celgene Corporation | $7,932 | 10 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $3,382 | 5 | $0 (2019) |
| Ethicon Inc. | $142.39 | 1 | $0 (2021) |
| Dendreon Pharmaceuticals LLC | $133.90 | 2 | $0 (2019) |
| JAZZ PHARMACEUTICALS INC. | $47.60 | 3 | $0 (2022) |
| Seattle Genetics, Inc. | $36.87 | 3 | $0 (2018) |
| Genentech USA, Inc. | $18.14 | 1 | $0 (2017) |
| Teva Pharmaceuticals USA, Inc. | $12.75 | 1 | $0 (2017) |
| Gilead Sciences, Inc. | $11.92 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $47.60 | 3 | JAZZ PHARMACEUTICALS INC. ($47.60) |
| 2021 | $154.31 | 2 | Ethicon Inc. ($142.39) |
| 2019 | $12,844 | 15 | Merck Sharp & Dohme Corporation ($5,100) |
| 2018 | $8,399 | 17 | Merck Sharp & Dohme Corporation ($6,838) |
| 2017 | $8,290 | 15 | Merck Sharp & Dohme Corporation ($6,068) |
All Payment Transactions
52 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/08/2022 | JAZZ PHARMACEUTICALS INC. | VYXEOS (Drug) | Education | In-kind items and services | $16.79 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 04/05/2022 | JAZZ PHARMACEUTICALS INC. | VYXEOS (Drug) | Education | In-kind items and services | $16.79 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 04/05/2022 | JAZZ PHARMACEUTICALS INC. | VYXEOS (Drug) | Education | In-kind items and services | $14.02 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/10/2021 | Ethicon Inc. | Monarch Platform (Device) | Food and Beverage | In-kind items and services | $142.39 | General |
| Category: Endo-Mechanical | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 12/18/2019 | PFIZER INC. | LORBRENA (Drug) | Education | In-kind items and services | $11.05 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2019 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $115.18 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 10/24/2019 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $18.72 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 09/18/2019 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| Category: Oncology | ||||||
| 08/22/2019 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Travel and Lodging | In-kind items and services | $240.25 | General |
| Category: Oncology | ||||||
| 08/22/2019 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Travel and Lodging | In-kind items and services | $163.56 | General |
| Category: Oncology | ||||||
| 08/22/2019 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 08/22/2019 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Travel and Lodging | In-kind items and services | $53.00 | General |
| Category: Oncology | ||||||
| 02/07/2019 | Celgene Corporation | Luspatercept (Drug) | Consulting Fee | Cash or cash equivalent | $3,292.50 | General |
| 02/07/2019 | Celgene Corporation | Luspatercept (Drug) | Travel and Lodging | Cash or cash equivalent | $469.92 | General |
| 02/07/2019 | Celgene Corporation | Luspatercept (Drug) | Travel and Lodging | Cash or cash equivalent | $173.80 | General |
| 02/07/2019 | Celgene Corporation | Luspatercept (Drug) | Food and Beverage | Cash or cash equivalent | $115.82 | General |
| 01/26/2019 | Celgene Corporation | Luspatercept (Drug) | Food and Beverage | In-kind items and services | $164.85 | General |
| 01/16/2019 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $4,950.00 | General |
| 01/16/2019 | Merck Sharp & Dohme Corporation | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 12/13/2018 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $56.66 | General |
| 12/13/2018 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $54.02 | General |
| 12/13/2018 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $46.12 | General |
| 12/12/2018 | Merck Sharp & Dohme Corporation | — | Travel and Lodging | In-kind items and services | $847.11 | General |
| 12/12/2018 | Merck Sharp & Dohme Corporation | — | Travel and Lodging | In-kind items and services | $173.39 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CC-4047-MM-007 - Safety and efficacy of pomalidomide, bortezomib, and low-dose dexamethasone in subjects with relapsed or refractory multiple myeloma | Celgene Corporation | $1,524 | 1 |
| MEDI4736-MM-005 | Celgene Corporation | $417.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 239 | 764 | $185,075 | $62,086 |
| 2022 | 6 | 299 | 887 | $201,030 | $67,659 |
| 2021 | 7 | 398 | 1,122 | $286,410 | $99,870 |
| 2020 | 8 | 446 | 1,579 | $359,165 | $112,211 |
Total Patients
1,382
Total Services
4,352
Medicare Billing
$341,825
Procedure Codes
39
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 57 | 288 | $66,610 | $22,322 | 33.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 61 | 240 | $55,505 | $18,517 | 33.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 17 | 51 | $17,340 | $5,934 | 34.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 21 | 49 | $16,660 | $5,764 | 34.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 21 | 56 | $9,240 | $3,679 | 39.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 14 | 14 | $6,020 | $2,071 | 34.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 11 | 11 | $4,730 | $1,685 | 35.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 19 | 30 | $4,800 | $1,222 | 25.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 18 | 25 | $4,170 | $892.64 | 21.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 52 | 256 | $58,810 | $20,140 | 34.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 38 | 185 | $42,095 | $14,933 | 35.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 46 | 135 | $25,235 | $8,094 | 32.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 26 | 53 | $17,295 | $5,633 | 32.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 50 | 89 | $13,505 | $4,410 | 32.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 16 | 35 | $11,475 | $3,988 | 34.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 21 | 22 | $11,040 | $3,688 | 33.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 37 | 73 | $11,060 | $3,393 | 30.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 13 | 39 | $10,515 | $3,381 | 32.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 50 | 240 | $54,255 | $19,128 | 35.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 29 | 135 | $42,525 | $16,918 | 39.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 45 | 124 | $39,160 | $15,350 | 39.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 50 | 165 | $37,125 | $13,179 | 35.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 46 | 56 | $32,200 | $9,605 | 29.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 40 | 122 | $25,010 | $7,509 | 30.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 31 | 79 | $23,305 | $6,988 | 30.0% |
About Dr. Peter Byeff, MD
Dr. Peter Byeff, MD is a Hematology & Oncology healthcare provider based in Southington, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/18/2005. The National Provider Identifier (NPI) number assigned to this provider is 1710979463.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Peter Byeff, MD has received a total of $29,735 in payments from pharmaceutical and medical device companies, with $47.60 received in 2022. These payments were reported across 52 transactions from 11 companies. The most common payment nature is "Consulting Fee" ($22,638).
As a Medicare-enrolled provider, Byeff has provided services to 1,382 Medicare beneficiaries, totaling 4,352 services with total Medicare billing of $341,825. Data is available for 4 years (2020–2023), covering 39 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Southington, CT
- Active Since 08/18/2005
- Last Updated 02/25/2008
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1710979463
Products in Payments
- Luspatercept (Drug) $4,217
- CALQUENCE (Drug) $3,382
- Revlimid (Drug) $1,774
- Pomalyst (Drug) $1,524
- Durvalumab (Drug) $417.00
- Monarch Platform (Device) $142.39
- PROVENGE (Drug) $133.90
- VYXEOS (Drug) $47.60
- ADCETRIS (Biological) $36.87
- Avastin (Biological) $18.14
- BENDEKA (Drug) $12.75
- LORBRENA (Drug) $11.05
- KEYTRUDA (Biological) $6.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.